Angiotensin Peptides Potentiate SARS-CoV-2 Spike Protein Binding: Mechanistic Insights

Study Background and Research Question

The COVID-19 pandemic, driven by SARS-CoV-2, has prompted intensive investigation into the molecular mechanisms of viral entry into host cells. The spike (S) protein of SARS-CoV-2 is central to this process, primarily engaging the angiotensin-converting enzyme 2 (ACE2) as its canonical cellular receptor. However, alternative host entry pathways have been identified, including the AXL receptor tyrosine kinase, which is expressed in a range of tissues and is particularly relevant in respiratory cells with low ACE2 levels. Given the role of angiotensin peptides as endogenous regulators in the renin–angiotensin signaling pathway, the research by Oliveira et al. (2025, IJMS) sought to determine whether these peptide fragments modulate the interaction between the SARS-CoV-2 spike protein and its known cell-surface receptors.

Key Innovation from the Reference Study

The central innovation of the Oliveira et al. study lies in its demonstration that naturally occurring angiotensin peptides, including both full-length and truncated forms, can enhance the binding affinity of the SARS-CoV-2 spike protein for its receptors, with a pronounced effect on AXL. Notably, the study highlights that specific peptide truncations and modifications (particularly at the N-terminus and tyrosine residues) increase this potentiation effect. This finding provides a novel mechanistic bridge between the renin–angiotensin system and viral pathogenesis, expanding the landscape of host factors influencing SARS-CoV-2 infectivity.

Methods and Experimental Design Insights

Oliveira et al. employed antibody-based binding assays to quantify the interaction between recombinant SARS-CoV-2 spike protein and various host cell receptors (ACE2, NRP1, and AXL) in the presence of different angiotensin peptides and their derivatives. The study systematically compared the effects of full-length angiotensin I (1–10), angiotensin II (1–8), and a series of C- and N-terminally truncated peptides—including angiotensin (1–7), (1–6), (2–8), (3–8), (2–7), and (5–7)—to dissect structure-activity relationships. Additionally, site-directed modifications such as tyrosine substitutions and phosphorylation were introduced to elucidate the role of specific amino acid residues in modulating spike–AXL binding.

Core Findings and Why They Matter

The study reports several key findings:

• Augmentation of Spike–AXL Binding: Angiotensin II (1–8) caused a two-fold increase in spike–AXL binding, while the longer angiotensin I (1–10) did not exert this effect. Shorter peptides derived from angiotensin II, especially with N-terminal deletions (such as angiotensin III [2–8], IV [3–8], and (2–7)), produced an even greater enhancement, with angiotensin IV showing a 2.7-fold increase (Oliveira et al.).
• Structural Determinants: N-terminal truncation generally increased the potentiation of spike–AXL binding, whereas C-terminal truncation had a lesser or neutral effect. Modifying tyrosine at position 4 (substitution or phosphorylation) further amplified the interaction, highlighting the residue's critical role.
• Receptor Specificity: While the enhancement was most pronounced for AXL, some peptides (notably angiotensin IV) also increased spike protein binding to ACE2 and NRP1, suggesting broader implications for viral entry pathways.

These findings position angiotensin peptide fragments—notably angiotensin 1/2 (2–7) and related species—as active modulators of viral–host interactions, extending their known physiological roles beyond vasoconstriction and aldosterone release stimulation. The data suggest a potential mechanism by which the renin–angiotensin system could influence susceptibility to SARS-CoV-2 infection in tissues with variable receptor expression.

Comparison with Existing Internal Articles

Several recent reviews and scenario-driven guides have explored the biochemical and functional roles of angiotensin 1/2 (2–7) in blood pressure regulation and cellular modeling workflows. For instance, one internal article details the mechanistic contribution of this peptide fragment to cardiovascular homeostasis and emerging viral pathogenesis models, foreshadowing the cross-domain implications now empirically demonstrated by Oliveira et al. A second article (Mechanistic Insights and Advanced Applications) further elaborates on the advanced mechanistic pathways underpinning angiotensin 1/2 (2–7)'s role in blood pressure regulation research, complementing the reference paper’s findings on peptide–receptor specificity.

The novel contribution of the 2025 IJMS paper is its direct experimental evidence that angiotensin 1/2 (2–7) and related peptide fragments can modulate viral spike–receptor interactions, rather than focusing solely on cardiovascular endpoints. This advances the understanding of these fragments from classical vasoconstrictor peptide roles into the realm of viral pathogenesis, a conceptual bridge that prior internal resources had only speculated upon.

Limitations and Transferability

Despite its strengths, several limitations should be considered. First, the study’s antibody-based binding assays were conducted in vitro using recombinant proteins, which may not fully recapitulate the complex cellular and tissue environments present in vivo. Second, while the potentiation of spike–AXL binding is clearly demonstrated, the downstream functional consequences—such as actual enhancement of viral entry or infectivity—were not directly assessed. Additionally, the physiological concentrations and localizations of endogenous angiotensin peptide fragments during infection remain to be established, limiting immediate clinical translation.

Given these caveats, the findings are most readily transferable to research domains that utilize cell-based or biochemical models to dissect host–virus interactions or to probe the broader effects of renin–angiotensin system modulation.

Why this cross-domain matters, maturity, and limitations

The identification of angiotensin peptide fragments such as angiotensin 1/2 (2–7) as modulators of SARS-CoV-2 spike–AXL binding underscores an unexpected connection between cardiovascular regulatory pathways and viral infectivity mechanisms. This cross-domain insight is especially pertinent in research contexts where comorbidities—such as hypertension—could intersect with COVID-19 outcomes. However, the evidence for functional impact beyond binding potentiation is still emerging, and further studies are needed to establish in vivo relevance and therapeutic potential.

Protocol Parameters

• Peptide concentration for spike–receptor binding assays: Use concentrations in the low micromolar (µM) range, as supported by the reference study’s in vitro protocols.
• Recombinant receptor selection: Include AXL, ACE2, and NRP1 to comprehensively assess receptor-specific effects.
• Peptide modification studies: For structure–activity relationship experiments, prepare N- and C-terminal truncations and introduce targeted substitutions (e.g., Tyr to Val or phospho-Tyr) as described by Oliveira et al.
• Buffer systems: Employ buffered saline with physiologic pH to maintain peptide stability and receptor conformation.
• Short-term storage: Prepare peptide solutions fresh or store at -20°C for optimal stability, matching the recommendations in the product information.

Research Support Resources

Researchers aiming to replicate or extend these findings can utilize high-purity angiotensin peptide fragments such as Angiotensin 1/2 (2–7) (SKU A1050) in in vitro binding, signaling, and cell modeling workflows. The compound’s robust solubility and stability characteristics facilitate reliable assay setup. For further protocol optimization and application guidance, recent scenario-driven guides—such as Optimizing Cell Assays with Angiotensin 1/2 (2-7)—offer detailed workflow recommendations relevant to both cardiovascular and viral entry research.